Stabilized composition comprising a benzimidazole type compound
The present invention provides a chemically stable pharmaceutical preparation of a benzimidazole type compound. That is, the present invention relates to a composition comprising at least one substance selected from sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, aminoalkyl methaacrylate copolymer E, arginine aspartate, hydroxypropyl cellulose and crospovidone incorporated into a benzimidazole type compound or an alkali metal salt thereof.
1 - 15 . (Canceled).
16 . A composition comprising (A) rabeprazole or an alkali metal salt thereof and (B) sodium hydroxide, wherein the composition comprises 1 part by weight of (A) and 0.01 to 2 parts by weight of (B).
17 . A composition comprising (A) rabeprazole or an alkali metal salt thereof, (B) crospovidone and sodium hydroxide, wherein the composition comprises 1 part by weight of (A), 0.01 to 2 parts by weight of sodium hydroxide and 0.5 to 5 parts by weight of crospovidone.
18 . A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 16 or 17 and an enteric coating thereon.
19 . A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 16 or 17 , an intermediate coating and an enteric coating.
20 . A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 16 or 17 , an intermediate coating, an enteric coating and a moisture resistant coating.
21 . The pharmaceutical composition of claim 16 or 17 wherein components (A) and (B) are uniformly mixed with each other.
22 . The pharmaceutical composition of claim 16 or 17 wherein (A) is mixed with a portion of (B) to form granules, then a further amount of (B) is added to the granules and mixed, then the mixture is formed into a tablet.
23 . The pharmaceutical composition of claim 16 or 17 wherein (A) is mixed with a portion of (B) and formed into a core, then a further amount of (B) is coated as a layer onto the core.
24 . A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 17 and an enteric coating.
25 . A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 17 , an intermediate coating and an enteric coating.
26 . A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 17 , an intermediate coating, an enteric coating and a moisture-resistant coating.
27 . The composition according to claim 17 , which further comprises an antioxidant.
28 . The pharmaceutical preparation according to any one of claims 24 , 25 or 26 , wherein the core further comprises an antioxidant.
29 . A pharmaceutical preparation comprising a core which comprises the composition of claim 16 or 17 coated with an enteric coating and further with a moisture-resistant coating.
30 . A pharmaceutical preparation comprising a core which comprises the composition of claim 16 or 17 coated with an intermediate coating, further with an enteric coating and then with a moisture-resistant coating.
31 . A composition comprising (A) rabeprazole or an alkali metal salt thereof and (B) sodium hydroxide, wherein the composition comprises 1 part by weight of (A) and 0.01 to 0.5 parts by weight of (B).
32 . A composition comprising (A) rabeprazole or an alkali metal salt thereof, (B) crospovidone and sodium hydroxide, wherein the composition comprises 1 part by weight of (A), 0.01 to 0.5 parts by weight of sodium hydroxide and 0.5 to 5 parts by weight of crospovidone.
33 . The composition according to claim 31 or 32 which comprises 1 part by weight of (A) and 0.05 parts by weight of (B).